Information Provided By:
Fly News Breaks for December 8, 2019
Dec 8, 2019 | 20:13 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $80 from $72 and reiterates an Overweight rating on the shares. Arrowhead expects to have three pivotal Phase III trials underway in 2020, and the company has pro forma cash of $554M to advance its wholly-owned TRiM pipeline, Tenthoff tells investors in a research note.
News For ARWR From the Last 2 Days
There are no results for your query ARWR